Filing identity and reporting period
Important identity mismatch: The supplied filing is JATT Acquisition Corp.’s Form 10-Q for the quarter ended March 31, 2022, not a filing by Zura Bio Ltd. It describes a Cayman Islands blank-check company searching for a business combination. The financial information below is for JATT.
Financial performance and position
- Revenue: No operating revenue; JATT stated it would not generate operating revenue before completing a business combination.
- Profit: Net income was $147,856, versus a $33,039 net loss in the period from inception through March 31, 2021. Q1 2022 income included a $543,870 noncash gain from the change in fair value of warrant liabilities and $16,299 of trust investment income, offset by $412,327 of operating expenses. The prior comparison is an inception-period figure, not a prior-year quarter.
- Expenses and margins: General and administrative expense was $322,327, plus $90,000 of related-party expense. Margins are not meaningful without operating revenue.
- Cash flow: Cash used in operating activities was $214,619. Cash declined from $729,223 at December 31, 2021 to $514,604 at March 31, 2022.
- Liquidity: Current assets were $836,951 and current liabilities $369,439, implying working capital of about $468,000. The $139.4 million held in the trust account is primarily reserved for a business combination or public-share redemptions, rather than ordinary operating liquidity.
- Debt and liabilities: No working-capital loans were outstanding at quarter-end. Total liabilities were $9.9 million, including $4.01 million of deferred underwriting commissions and $5.53 million of warrant liabilities. The balance sheet also shows $139.38 million of Class A shares classified as subject to possible redemption and a $9.03 million shareholders’ deficit.
Changes, outlook, and risks
- Management reported substantial doubt about JATT’s ability to continue as a going concern through the earlier of a business combination or required liquidation, citing expected cash needs and the January 16, 2023 liquidation deadline. The statements include no liquidation adjustments.
- In January 2022, forward purchase commitments were reduced from $75 million to $30 million. The amended agreements also provide for a $15 million redemption backstop if redemptions exceed 90% and $30 million of bridge financing to the target, evidenced by a convertible note. These commitments are conditional on a transaction.
- On May 11, 2022, after quarter-end, a Sponsor affiliate agreed to provide up to $300,000 under a non-interest-bearing note for expenses. It may be converted into warrants at the lender’s discretion; it would terminate if no business combination closes before January 13, 2023.
- Disclosure controls were deemed ineffective due to a material weakness in accounting for complex financial instruments. Management described additional review procedures and remediation work, but gave no assurance the remediation would be successful.
- Management cited potential COVID-19 effects on the company and its target search as not readily determinable. It also warned that proposed SEC rules for SPAC transactions could increase costs and hinder completion of a business combination.
- No business-combination guidance or forecast was provided. If no combination is completed by January 16, 2023, JATT must cease operations, redeem public shares and proceed toward liquidation under the stated terms.
Key facts investors should verify
- Confirm the filing belongs to the intended issuer: the supplied report names JATT Acquisition Corp., not Zura Bio Ltd.
- Reconcile related-party expense disclosures: the statements report $90,000 for the quarter; the notes describe $30,000 of Sponsor support plus $60,000 of affiliate services, while MD&A refers to approximately $98,000 for affiliate services.
- Review the amended forward purchase and redemption-backstop terms, including conditions, funding availability, and the convertible bridge note’s potential dilution.
- Assess whether operating cash and the subsequent $300,000 note are sufficient to fund expenses through the transaction deadline; the lender is not obligated to provide the full amount under the terms summarized.
- Track remediation of the material weakness and any subsequent changes to controls or financial-instrument accounting.